Every 8-K that Kiora Pharmaceuticals, Inc. (KPRX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow KPRX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full KPRX filings page.
Kiora Pharmaceuticals, Inc. (KPRX) appointed Keith J. Lane as Executive Vice President, Head of Clinical Development and Regulatory Affairs effective September 8, 2026. Lane brings over 20 years of ophthalmology-focused clinical development and regulatory experience, including leadership at Ora, Inc. and oversight of more than 60 ophthalmic clinical trials.
Under a June 22, 2026 Offer Letter, Lane will receive a $350,000 annual base salary, a $75,000 sign-on bonus, and is eligible for an annual performance bonus targeted at up to 35% of base salary. Subject to Compensation Committee approval under the 2024 Equity Incentive Plan, he will be granted an option to purchase up to 55,000 shares of Kiora common stock, vesting one-third on the first anniversary of the grant and monthly over the following two years. Kiora also furnished a press release announcing the hiring as an exhibit.
Kiora Pharmaceuticals, Inc. (KPRX) entered into an Exclusive License and Development Agreement with Chong Kun Dang Pharmaceutical Corporation (CKD) covering its KIO-301 molecular photoswitch program. CKD receives an exclusive, sublicensable license to develop, manufacture, commercialize and seek regulatory approvals for KIO-301 in South Korea for retinitis pigmentosa and other ophthalmic diseases.
Under the agreement, Kiora will receive a $1 million up-front payment and is eligible for additional development, regulatory and sales milestone payments, plus double digit royalties on net sales in South Korea, subject to adjustments. CKD will lead development and commercialization in South Korea, while Kiora expects CKD, Laboratoires Théa and Senju Pharmaceutical to coordinate a single global Phase 3 trial for KIO-301 in retinitis pigmentosa.
Kiora highlights that this deal fills the last major unpartnered market for KIO-301 and allows internal resources to focus on KIO-104 for retinal inflammation and fibrosis and evaluation of ion channel modulators for non-ophthalmic uses, alongside potential strategic pipeline-expansion transactions.
Kiora Pharmaceuticals reported financial results for the second quarter ended June 30, 2026, alongside updates on its retinal-disease pipeline. Enrollment has advanced into the higher 100 µg dose cohort of the Phase 2 ABACUS-2 trial of KIO-301 for late-stage retinitis pigmentosa, with an independent safety review planned after the first few higher-dose patients are treated. The company expects the last patient, first visit in the first quarter of 2027 and topline data in the third quarter of 2027. Development costs for ABACUS-2 are fully reimbursed under Kiora’s collaboration with Théa Open Innovation, which holds exclusive rights to KIO-301 in the U.S., Europe and other select territories outside Asia.
For KIO-104, a non-steroidal DHODH inhibitor for retinal inflammation and macular edema, patients are being enrolled into the higher-dose group of the Phase 2 KLARITY trial, with initial clinical data expected in late 2026. Kiora is also evaluating potential strategic transactions to diversify its pipeline, which could trigger warrant exercises linked to a recent financing, and is assessing partnering options across Asian territories, including an option agreement with Senju and a potential commercial partner in South Korea.
Kiora ended the quarter with approximately $16.8 million in cash and short-term investments, up from $13.9 million at March 31, 2026, and has secured a private placement for up to $24.0 million in gross proceeds, including $5.0 million already received. Based on its operating plan, collaboration reimbursements and available capital, the company expects to fund operations into late 2028. Research and development expenses were $2,077,116 before $1,336,263 in collaboration credits, general and administrative expenses were $1,383,504, and net loss was $2,079,010, or $0.34 per share, for the second quarter of 2026.
Kiora Pharmaceuticals filed a current report describing new preclinical data for its ion channel modulator platform. The company reported that KIO-300, the active ingredient in its Phase 2 vision restoration drug KIO-301, significantly suppressed seizure-associated electrical activity in an ex vivo temporal lobe epilepsy model.
The effect reduced spontaneous epileptiform event frequency versus vehicle controls and remained during treatment and washout, while broader electrical transmission in brain tissue was preserved. These findings, presented at the Epilepsy Foundation Pipeline Conference, support potential applications of KIO-300 in epilepsy and other neurological disorders beyond ophthalmology.
Kiora Pharmaceuticals, Inc. reported results from its 2026 annual meeting of stockholders. Stockholders approved an amendment to the 2024 Equity Incentive Plan, increasing the shares of common stock authorized for issuance under the plan by 1,500,000 shares.
Three Class II directors — Lisa Walters-Hoffert, Aron Shapiro, and Praveen Tyle, Ph.D. — were re-elected for terms running until the 2029 annual meeting, with over 1,029,000 votes cast for each nominee. Stockholders also approved, on a non-binding advisory basis, the compensation of the company’s named executive officers.
Haskell & White LLP was ratified as independent registered public accounting firm for the fiscal year ending December 31, 2026, receiving 2,358,943 votes for, 5,403 against, and 1,983 abstentions.
Kiora Pharmaceuticals reported first quarter 2026 results, highlighting clinical progress in its retinal disease pipeline and a modestly higher net loss. The company recorded a net loss of $2.4 million for the quarter, or $0.58 per basic and diluted share.
Kiora ended March 31, 2026 with $13.9 million in cash and short-term investments and subsequently raised an additional $5.0 million through a strategic equity financing. Management believes this supports an operational runway into late 2028, beyond anticipated data readouts from its KIO-301 ABACUS-2 and KIO-104 KLARITY Phase 2 trials.
Enrollment in ABACUS-2 for KIO-301 is roughly half complete, supported by strong patient demand and expanded trial sites, and prior ABACUS-1 data were published in Nature Medicine. KIO-104 continues in the KLARITY study, with a planned safety review expected to enable escalation to a higher dose cohort.
Kiora Pharmaceuticals entered into a private placement with institutional investors Perceptive Advisors and ADAR1 Capital Management, raising $5.0 million upfront and providing up to an additional $19.0 million in potential warrant exercise proceeds. The deal includes 438,471 common shares, pre-funded warrants for 1,527,711 shares, and Tranche A-1 and A-2 warrants for up to 9,830,909 additional shares at an exercise price of $1.94 per share. Warrants are immediately exercisable and have milestone-based terms tied to strategic transactions and completion of Phase 3 trial enrollment. The securities were issued under Regulation D exemptions and will later be registered for resale under a planned registration statement.
Kiora Pharmaceuticals announced that Chief Development Officer Eric J. Daniels, M.D., MBA will resign effective April 17, 2026 to pursue another opportunity. The company stated his departure is not due to any disagreement over operations, policies, or practices and has begun a search for his successor.
Kiora emphasized continued progress in its retinal disease pipeline. In the ABACUS-2 Phase 2 trial of KIO-301, a planned safety review allowed enrollment of remaining patients in the 50µg dose cohort and cleared initiation of the 100µg cohort. In the KLARITY Phase 2 trial of KIO-104, all planned safety checkpoints have been cleared and patient enrollment is ongoing.
Kiora Pharmaceuticals reported a net loss of $10.8 million for 2025, compared with net income of $3.6 million in 2024, mainly because 2024 included $16.0 million of collaboration revenue and 2025 recorded a $4.6 million in-process R&D impairment related to KIO-104.
Revenue was zero in 2025, while operating expenses rose as R&D increased to $10.8 million with two Phase 2 trials underway and G&A reached $5.7 million. Kiora ended 2025 with $17.1 million in cash, cash equivalents and short-term investments plus $3.5 million in receivables and projects its cash runway into late 2027.
Pipeline progress included advancing KIO-301 and KIO-104 into active Phase 2 studies in retinal diseases and signing an option agreement with Senju Pharmaceutical with potential value of up to $110 million plus royalties, alongside continued work on the KIO-300 ion-channel modulator platform.
Kiora Pharmaceuticals (KPRX) furnished an 8-K announcing it issued a press release with financial results for the quarter ended September 30, 2025 and an update on clinical development progress. The press release is included as Exhibit 99.1.
The company stated the information under Item 2.02, including Exhibit 99.1, is furnished, not filed, and will not be incorporated by reference into other filings unless specifically stated. Kiora’s common stock trades on NASDAQ under the symbol KPRX.
Kiora Pharmaceuticals, Inc. reported via an 8-K that on August 8, 2025 it issued a press release announcing financial results for the quarter ended June 30, 2025 and provided an update on its clinical development progress. The press release is furnished as Exhibit 99.1 and an Inline XBRL cover page is included as Exhibit 104. The filing states that the furnished information, including Exhibit 99.1, is not deemed "filed" under Section 18 and is not incorporated by reference into other Securities Act or Exchange Act filings except where expressly stated.
The report is signed by Melissa Tosca, Chief Financial Officer. No financial line-item figures or clinical data are presented within the 8-K text itself; readers must refer to Exhibit 99.1 for the detailed press release content.